Last updated: July 14, 2026
ecutive summary
Array BioPharma (Nasdaq: ARRY) vs Eugia Pharma Specialities (Eugia) in D. Delaware, No. 1:22-cv-01236 is framed around a Paragraph IV dispute and centers on Array’s Orange Book-listed IP for a specific Array commercial product. The public docket record and filings determine the case posture, asserted patents, and which claims were challenged. Without the underlying docket contents (complaint, patent list, ANDA/suit-triggering notice, counterclaims, claim constructions, and any settlement terms), a litigation-accurate summary cannot be produced.
Litigation summary for Array BioPharma v. Eugia Pharma Specialities (1:22-cv-01236)
No complete litigation summary can be stated from the case caption alone. A litigation summary requires at least one of: asserted patent numbers, asserted claims, the ANDA/BLA product and NDA number, the procedural milestones (motions to dismiss, transfer, claim construction scheduling order), Markman outcome, injunction or covenant terms, and whether the case reached trial or settled.
What is the case about in 1:22-cv-01236?
A “what the case is about” summary depends on:
- the litigated FDA product (NDA/ANDA holder and reference listed drug),
- the Orange Book patents asserted (and whether the suit is a usual Paragraph IV “§ 271(e)(2)” case),
- the defenses asserted by Eugia (invalidity, non-infringement, statutory bars),
- Array’s requested relief (temporary restraining order/preliminary injunction versus declaratory judgment).
None of those inputs are provided.
What patents are asserted, and what claims are in dispute?
A defensible patent-and-claim summary requires the complaint’s asserted patent list and claim mappings or infringement allegations. The docket number does not expose:
- patent numbers and expiration dates,
- whether the asserted patents are composition, formulation, method-of-use, or manufacturing,
- whether Eugia challenged all asserted patents or only a subset,
- whether Eugia alleged non-infringement or invalidity as well as non-infringement-for-each-claim.
Procedural timeline: what happened when?
A litigation timeline needs docket events such as:
- filing date and first responsive pleadings,
- motion practice (dismissal, summary judgment, venue transfer),
- Markman schedule and claim construction order date,
- any stipulations dismissing parties or patents,
- trial scheduling, dispositive rulings, and final judgment.
Those events are not available in the prompt.
Patent estate context: which Array product is involved and how strong is the asserted IP?
A litigation analysis ties the asserted patents to:
- Orange Book status and listing type (drug substance, drug product, method-of-use),
- remaining life at filing (patent expiration and exclusivity),
- litigation history of the same patents (prior settlements, Federal Circuit guidance),
- likelihood-of-infringement posture based on the claimed formulation or method.
The specific Array product and asserted patent set are not identified, so strength scoring or barrier assessment cannot be performed.
What would Array have to prove in this case?
In an ANDA Paragraph IV case under 35 U.S.C. § 271(e)(2), Array typically must establish infringement of each asserted claim as it is practiced in the accused ANDA product, and the claims that Eugia challenged as invalid must survive Eugia’s invalidity theories.
A litigation-grade proof breakdown requires knowing:
- whether Eugia’s ANDA product was for a drug product, formulation, or method-of-use claim,
- the claim elements that were contested,
- whether claim construction occurred and which terms were construed,
- the factual record (experiments, labeling, equivalency, or product composition).
The prompt does not supply those facts.
What generic entry risks exist for Eugia, and what does it signal for other Paragraph IV filers?
A risk analysis depends on:
- whether the case settled (and on what effective date),
- whether there was an injunction or a stipulation to a design-around,
- whether the court ruled on validity or infringement (and with what holdings).
Without settlement terms, judgments, or injunction/covenant information, no entry-risk evaluation can be made.
How to interpret settlement leverage and damages exposure without docket outcomes?
Settlement leverage can be inferred only from concrete outcomes:
- if Array obtained a preliminary injunction, Eugia’s commercial timeline is constrained;
- if a final judgment found infringement and non-invalidity, payout or launch dates are tightly controlled;
- if Eugia prevailed on key claims, the patent barrier collapses for future applicants.
The prompt provides none of those outcomes.
Key takeaways
- The case caption 1:22-cv-01236 alone is insufficient to generate an accurate litigation summary or legal analysis.
- A litigation summary must include the asserted patents, FDA product identity, procedural milestones, and final disposition. Those elements are not present.
- No defensible conclusions can be made regarding patent strength, likely outcomes, or generic entry timing without docket record specifics.
FAQs
- What asserted patents are tied to Array BioPharma’s 1:22-cv-01236 case against Eugia?
- Was the case resolved by settlement, dismissal, or final judgment?
- Did the court issue any claim construction orders or injunction-related rulings?
- Which FDA filing triggered the Paragraph IV dispute in 1:22-cv-01236?
- How does the case affect launch risk for other ANDA applicants on the same Orange Book listings?
References
No sources were cited because no docket content, complaint, or court orders were provided in the prompt.
